Rauth A M, Goldberg Z, Misra V
Division of Experimental Therapeutics, Ontario Cancer Institute, Toronto,
Oncol Res. 1997;9(6-7):339-49.
DT-diaphorase [also called NAD(P)H:menadione oxidoreductase; NAD(P)H:(quinone acceptor) oxidoreductase; quinone reductase, azo-dye reductase] (EC.1.6.99.2) has been shown to have a role in activation of quinone-containing cancer chemotherapeutic prodrugs to their active form, as well as inactivation of a variety of xenobiotics involved in carcinogenesis. To illustrate the basis of this dichotomy, a brief review of the historical and recent background of studies on DT-diaphorase is given. Recent data from the laboratory of the authors on the nature of the protein coded for by a recently identified human polymorphism, a C to T transition at nucleotide 609 of DT-diaphorase cDNA, and the frequency of this mutation in anal canal carcinoma patients is presented. Finally, a series of questions about the role of DT-diaphorase in both normal and malignant cells is raised based on the results of others that have been published in the last 2-3 years.
DT-黄递酶也称为NAD(P)H:甲萘醌氧化还原酶;NAD(P)H:(醌受体)氧化还原酶;醌还原酶、偶氮染料还原酶已被证明在含醌的癌症化疗前体药物激活为其活性形式以及参与致癌作用的多种外源性物质失活过程中发挥作用。为了阐明这种二分法的基础,本文简要回顾了DT-黄递酶研究的历史和近期背景。本文作者实验室提供了关于最近鉴定出的人类多态性所编码蛋白质的性质、DT-黄递酶cDNA第609位核苷酸由C到T的转变以及肛管癌患者中这种突变频率的最新数据。最后,根据过去两三年发表的其他研究结果,提出了一系列关于DT-黄递酶在正常细胞和恶性细胞中作用的问题。